Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022008716 - MicroRNA-TARGETED THERAPY FOR CARDIAC REPAIR

Publication Number WO/2022/008716
Publication Date 13.01.2022
International Application No. PCT/EP2021/069151
International Filing Date 09.07.2021
IPC
C12N 15/113 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
A61P 9/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
Applicants
  • CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN [DE]/[DE]
Inventors
  • JAKOB, Philipp
  • LANDMESSER, Ulf
  • HARSHA VARDHAN, Renikunta
Agents
  • GULDE & PARTNER PATENT- UND RECHTSANWALTSKANTLEI MBB
Priority Data
20185192.010.07.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) MicroRNA-TARGETED THERAPY FOR CARDIAC REPAIR
(FR) THÉRAPIE CIBLÉE PAR MICRO-ARN POUR LA RÉPARATION CARDIAQUE
Abstract
(EN) The invention is directed to a miRNA with a RNA sequence comprising or consisting of hsa-miR-515-3p with SEQ ID NO: 1, and hsa-miR-519e-3p with SEQ ID NO:2, or a member of the miR-517 family, specifically hsa-miR-517c-3p, hsa-miR-517a-3p, or a primary transcript thereof, a precursor thereof, a mimic thereof or a combination for use as a medicament, preferably for use in treatment of a cardiac disease associated with loss of cardiac myocytes.
(FR) L'invention concerne un miARN avec une séquence d'ARN comprenant ou consistant en hsa-miR-515-3p avec SEQ ID NO : 1, et hsa-miR-519e-3p avec SEQ ID NO : 2, ou un membre de la famille miR-517, spécifiquement hsa-miR-517c-3p, hsa-miR-517a-3p, ou un transcrit primaire de celui-ci, un précurseur de celui-ci, un mimétique de celui-ci ou une combinaison pour une utilisation comme médicament, de préférence pour une utilisation dans le traitement d'une maladie cardiaque associée à une perte de myocytes cardiaques.
Latest bibliographic data on file with the International Bureau